S1P Receptor Agonists via Local Quality Modifications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel, potent, and selective agonists of the S1P receptor with enhanced potency, selectivity, and oral bioavailability, as well as methods for their identification and synthesis.
Innovation Solution
The development of a compound of formula (I) with specific structural features, including various functional groups and bonds, which can act as a pharmaceutically acceptable salt or prodrug, and a method for its synthesis involving the use of a compound with a cycloalkyl or heterocyclyl group, to provide agonism of sphingosine 1-phosphate receptors for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing S1P agonists are used, then receptor activation is achieved, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies local quality by modifying specific regions of the S1P molecule structure. The compound features a sphingosine backbone with specific substitutions at defined positions (e.g., hydroxyl groups, amino groups, and side chains) to enhance binding affinity and selectivity for particular S1P receptor subtypes while maintaining overall receptor activation capability
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, chain lengths, and functional group configurations in the S1P analog structure. These parameter modifications optimize the balance between potency (receptor binding strength) and selectivity (preference for specific receptor subtypes)
2Reliability
If S1P agonist activity is enhanced, then therapeutic efficacy is improved, but oral bioavailability may be compromised
Solution Approach 1:
The patent applies parameter changes by modifying physicochemical properties of the S1P analog, such as adding polar groups or adjusting molecular weight, to improve oral bioavailability while preserving the core pharmacophore necessary for S1P receptor activation and therapeutic efficacy
Solution Approach 2:
The patent uses intermediary structures such as prodrug moieties or solubilizing groups that facilitate oral absorption and distribution of the active compound, allowing the potent S1P agonist to reach its target receptors effectively after oral administration
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.